Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells

Cancer Research

Volumn 58, Issue 14, 1998, Pages 3051-3058

  Würflein, Dieter ^a   Dechant, Michael ^a   Stockmeyer, Bernhard ^a   Tutt, Alison L ^d   Hu, Peisheng ^b   Repp, Roland ^a   Kalden, Joachim R ^a   Van De Winkel, Jan G J ^c   Epstein, Alan L ^b   Valerius, Thomas ^a   Glennie, Martin ^d   Gramatzki, Martin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD64 ANTIGEN; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G1;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOLOGY; CONTROLLED STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; LEUKEMIA; MONONUCLEAR CELL; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; B-LYMPHOCYTES; GRANULOCYTE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DP ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, B-CELL; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, B-CELL; RECEPTORS, IGG; TUMOR CELLS, CULTURED;

EID: 2642651103     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bailar, J. C., III, and Gornik, H. L. Cancer undefeated. N. Engl. J. Med., 336: 1569-1574, 1997.
2. Dillman, R. O. Antibodies as cytotoxic therapy. J. Clin. Oncol., 12: 1497-1515, 1994.
3. Grossbard, M. L., Press, O. W., Appelbaum, F. R., Bernstein, I. D., and Nadler, L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood, 80: 863-878, 1992.
4. Miller, R. A., Maloney, D. G., Warnke, R., Levy, R. Treatment of B-cell lymphomas with monoclonal antiidiotype antibody. N. Engl. J. Med., 306: 517-522, 1982.
5. Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E., Rabb, R., Newman, R. A., Hanna, N., Anderson, D. R. Depletion of B-cells in vivo by a chimeric mouse human monclonal antibody to CD20. Blood, 83: 435-445, 1994.
6. Dyer, M. J. S., Hale, G., Hayhoe, F. G. J., and Waldman, H. Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood, 73: 1431-1439, 1989.
7. Lichtenstein, A. Granulocytes as possible effectors of tumor immunity. In: H. F. Oettgen (ed.), Human Cancer Immunology I, pp. 731-746. Philadelphia: W. B. Saunders, 1990.
8. Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Colombo, M. P., Lollini, P. L., and Forni, G. Cytokines, tumour-cell death and immunogenicity: a question of choice, Immunol. Today, 18: 32-36, 1997.
9. Stockmeyer, B., Valerius, T., Repp, R., Heijnen, I. A. F. M., Bühring, H. J., Deo, Y. M., Kalden, J. R., Gramatzki, M., and van de Winkel, J. G. J. Preclinical studies with FcγR bispecific antibodies and G-CSF primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res., 57: 696-701, 1997.
10. Platzer, E. Human hematopoietic growth factors. Eur. J. Haematol., 42: 1-15, 1989.
11. Fanger, M. W., Shen, L., Graziano, R. F., and Guyre, P. M. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today, 10: 92-99, 1989.
12. Morton, H. C., van Egmond, M., and van de Winkel, J. G. J. Structure and function of human IgA Fc receptors (FcαR). Crit. Rev. Immunol., 16: 423-440, 1996.
13. Ravetch, J. V. Fc receptors. Curr. Opin. Immunol., 9: 121-125, 1997.
14. Cambier, J. C. Antigen, and Fc receptor signalling. J. Immunol., 155: 3281-3285, 1995.
15. Indik, Z. K., Park, J. G., Hunter, S., and Schreiber, A. D. The molecular dissection of Fcγ receptor mediated phagocytosis. Blood, 86: 4389-4399, 1995.
16. van de Winkel, J. G. J., and Capel, P. J. A. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today, 14: 215-221, 1993.
17. Guyre, P. M., Morganelli, P. M., and Miller, R. Recombinant immune interferon increases immunoglobulin Fc receptors on cultured human mononuclear phagocytes. J. Clin. Invest., 72: 393-397, 1983.
18. Repp, R., Valerius, T., Sendler, A., Gramatzki, M., Iro, H., Kalden, J. R., and Platzer, E. Neutrophils express the high affinity receptor for IgG (Fc-gamma RI; CD64) after in vivo application of rhG-CSF. Blood, 78: 885-889, 1991.
19. Valerius, T., Stockmeyer, B., van Spriel, A. B., Graziano, R. F., van den Herik-Oudijk, I. E., Repp, R., Deo, Y. M., Lund, J., Kalden, J. R., Gramatzki, M., and van de Winkel, J. G. J. FcαRI (CD89) as a novel trigger molecule for bispecific antibodies. Blood, 90: 4485-4492, 1997.
20. Elsässer, D., Valerius, T., Repp, R., Weiner, G. J., Deo, Y., Kalden, J. R., van de Winkel, J. G. J., Stevenson, G. T., Glennie, M. J., and Gramatzki, M. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with G-CSF. Blood, 87: 3803-3812, 1996.
21. Bonnard, G. D., Yasaha, K., and Maca, R. D. Continued growth of functional human T lymphocytes: production of human T-cell growth factor. Cell. Immunol., 51: 390-401, 1980.
22. Burger, R., Gebhardt, E., Trautmann, U., Hansen-Hagge, T. E., Strobel, G., Bartram, C., Kalden, J. R., and Gramatzki, M. Two new interleukin-6 dependent plasma cell lines carrying a chromosomal abnormality involving the IL-6 gene locus. Br. J. Haematol., 87: 212, 1994.
23. Epstein, A. L., Marder, R., Winer, J. N., Stathopoulos, E., Chen, F. M., Parker, J. W., and Tyalor, C. R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
24. Hu, P., Glasky, M. S., Yun, A., Alauddin, M. M., Hornick, J. L., Khawali, L. A., and Epstein, A. L. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum. Antib. Hybrid., 6: 57-67, 1995.
25. 2 and F(ab′)3 antibody derivatives. In: G. Gallagher, R. C. Rees, and C. W. Reynolds (eds.), Tumour Immunobiology: A Practical Approach, pp. 225-244. Oxford: Oxford University Press, 1995.
26. Stevenson, G. T., Glennie, M. J., and Kan, K. S. Chemically engineered chimeric and multi-Fab antibodies. In: M. Clark (ed.), Protein Engineering of Antibody Molecules, pp. 127-138. Nottingham, United Kingdom: Academic Titles, 1993.
27. Vaickus, L., Biddle, W., Cemerlic, D., and Foon, K. A. Interferon γ augments Lym-1-dependent, granulocyte-mediated tumor cell lysis. Blood, 75: 2408-2416, 1990.
28. Cemerlic, D., Dadey, B., Han, T., and Vaickus, L. Cytokine influence on killing of fresh chronic lymphocytic leukemia cells by human leukocytes. Blood, 77: 2707-2715, 1991.
29. Ottonello, L., Morone, P., Dapino, P., and Dallegri, F. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood, 87: 5171-5178, 1996.
30. Funakoshi, S., Hirano, A., Beckwith, M., Asai, O., Tian, Z., Hormick, J. L., Hu, P., Khawli, L. A., Epstein, A. L., Longo, D. L., and Murphy, W. J. Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivo. Blood, 90: 3160-3166, 1997.
31. Truman, J. P., Choqueux, C., Tschopp, J., Vedrenne, J., Le Deist, F., Charron, D., and Mooney, N. HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Blood, 89: 1996-2007, 1997.
32. Bridges, S. H., Kruisbeek, A. M., and Longo, D. L. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on a B cell lymphoma. J. Immunol., 139: 4242-4249, 1987.
33. Gill, I., Agah, R., Hu, E., and Mazumder, A. Synergistic effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo. Cancer Res., 49: 5377-5379, 1989.
34. Fultz, M., Carman, J., Finkelman, F. D., and Mond, J. J. Neonatal suppression with anti-la antibody. III. In vivo responses to the type 2 antigen TNP-ficoll. J. Immunol., 143: 403-406, 1989.
35. Marx, J. L. Suppressing autoimmunity in mice. Science (Washington DC), 221: 843-845, 1983.
36. Hu, E., Epstein, A. L., Naeve, G. S., Gill, I., Martin, S., Sherrod, A., Nichols, P., Chen, D., Mazumder, A., and Levine, A. M. A Phase Ia clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol. Oncol., 7: 155-166, 1989.
37. DeNardo, G. L., Lewis, J. P., DeNardo, S. J., and O'Grady, L. F. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer (Phila.), 73: 1425-1432, 1994.
38. Lewis, J. P., De Nardo, G. L., and DeNardo, S. J. Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma, 14: 115-120, 1995.
39. Gingrich, R. D., Dahle, C. E., Hoskins, K. F., and Senneff, M. J. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood, 75: 2375-2387, 1990.
40. Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., and Neuberger, M. S. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med., 166: 1351-1361, 1987.
41. Ghetie, V., and Ward, E. S. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol. Today, 18: 592-598, 1997.
42. Heijnen, I. A. F. M., Rijks, L. J. M., Schiel, A., Stockmeyer, B., van Ojik, H. H., Dechant, M., Valerius, T., Keler, T., Tutt, A. L., Glennie, M. J., van Royen, E. A., Capel, P. J. A., and van de Winkel, J. G. J. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of PMN by combined administration of G-CSF and FcγRI bispecific antibodies. J. Immuonol., 159: 5629-5639, 1997.
43. Deo, Y. M., Graziano, R. F., Repp, R., and van de Winkel, J. G. J. Clinical significance of IgG receptors and FcγR-directed immunotherapies. Immunol. Today, 18: 127-135, 1997.
44. Valerius, T., Stockmeyer, B., and van de Winkel, J. G. J. Use of Filgrastim (r-metHuG-CSF) to enhance Fc receptor function. In: G. Morstyn and T. M. Dexter (eds.), Filgrastim (r-metHuG-CSF) in Cinical Practice, Ed. 2, pp. 73-92. New York: Marcel Dekker, 1998.
45. Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis. L. D., Memoli, V., Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., Mrozek-Orlowski, M., Wardwell, K., Guyre, V., Morley, T. L., Azvizu, C., and Fanger, M. W. Phase Ia/Ib trial of bispecific antibody MDX-210 (anti-Her-2/neu x anti-FcγRI) in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol., 13: 2281-2292, 1995.
46. Curnow, R. T. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol. Immunother., 45: 210-215, 1997.
47. Weiner, L. M., Clark, J. I., Davey, M., Li, W. S., de Palazzo, I. G., Ring, D. B., and Alpaugh, R. K. Phase I trial of 2BI, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res., 55: 4586-4593, 1995.
48. Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., and Pfreundschuh, M. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood, 89: 2042-2047, 1997.
49. van de Winkel, J. G. J., Bast, B., and de Gast, G. C. Immunotherapeutic potential of bispecific antibodies. Immunol. Today, 18: 562-564, 1997.